Search Results - "BERETTA, G. D"

Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trial by Labianca, R., Sobrero, A., Isa, L., Cortesi, E., Barni, S., Nicolella, D., Aglietta, M., Lonardi, S., Corsi, D., Turci, D., Beretta, G.D., Fornarini, G., Dapretto, E., Floriani, I., Zaniboni, A.

“…In advanced colorectal cancer, chemotherapy is usually administered without pauses and until progression but patients can experience cumulative toxicity and…”
Get full text

Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey by Ceresoli, G L, Grosso, F, Zucali, P A, Mencoboni, M, Pasello, G, Ripa, C, Degiovanni, D, Simonelli, M, Bruzzone, A, Dipietrantonj, C, Piccolini, E, Beretta, G D, Favaretto, A G, Giordano, L, Santoro, A, Botta, M

“…Background: The incidence of malignant pleural mesothelioma (MPM) in elderly patients is increasing. There are no specific guidelines for their management…”
Get full text

Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study by De Paoli, A., Chiara, S., Luppi, G., Friso, M.L., Beretta, G.D., Del Prete, S., Pasetto, L., Santantonio, M., Sarti, E., Mantello, G., Innocente, R., Frustaci, S., Corvò, R., Rosso, R.

“…Background: The aim of the study was to evaluate tolerance and efficacy of preoperative treatment with capecitabine in combination with radiation therapy (RT)…”
Get full text

Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Labianca, R, Nordlinger, B, Beretta, G D, Mosconi, S, Mandalà, M, Cervantes, A, Arnold, D

Get full text

A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation by Cascinu, S, Berardi, R, Salvagni, S, Beretta, G D, Catalano, V, Pucci, F, Sobrero, A, Tagliaferri, P, Labianca, R, Scartozzi, M, Crocicchio, F, Mari, E, Ardizzoni, A

“…Interesting activity has been reported by combining chemotherapy with cetuximab. An alternative approach for blocking EGFR function has been the development of…”
Get full text

Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up by Labianca, R., Nordlinger, B., Beretta, G. D., Brouquet, A., Cervantes, A.

Get full text

High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) by CASCINU, S, SCARTOZZI, M, BERETTA, G. D, GRAZIANO, F, BERARDI, R, FRANCIOSI, V, LABIANCA, R, CATALANO, V, SILVA, R. R, BARNI, S, ZANIBONI, A, D'ANGELO, A, SALVAGNI, S, MARTIGNONI, G

“…The aim of the present study was to evaluate the role of a weekly preoperative chemotherapy in locally advanced, unresectable gastric cancer. In all, 82…”
Get full text

Colorectal cancer: screening by Labianca, R., Beretta, G.D., Mosconi, S., Milesi, L., Pessi, M.A.

Get full text

Agreement between oncology guidelines and clinical practice in Italy: the ‘right’ program. A project of the Italian Association of Medical Oncology (AIOM) by Barni, S, Venturini, M, Beretta, GD, Gori, S, Molino, A, Carnaghi, C, Labianca, R, Sgarbi, S, Simoni, L, Maiello, E

“…Background: RIGHT (Research for the Identification of the most effective and hIGhly accepted clinical guidelines for the cancer Treatment) is a project…”
Get full text

Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) by Cascinu, S., Labianca, R., Catalano, V., Barni, S., Ferraù, F., Beretta, G. D., Frontini, L., Foa, P., Pancera, G., Priolo, D., Graziano, F., Mare, M., Catalano, G.

“…Background: This phase II study was initiated to determine the activity and toxicity of a combination of gemcitabine (GEM) and cisplatin (CDDP) in patients…”
Get full text

The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies by Russo, A., Incorvaia, L., Del Re, M., Malapelle, U., Capoluongo, E., Gristina, V., Castiglia, M., Danesi, R., Fassan, M., Giuffrè, G., Gori, S., Marchetti, A., Normanno, N., Pinto, C., Rossi, G., Santini, D., Sartore-Bianchi, A., Silvestris, N., Tagliaferri, P., Troncone, G., Cinieri, S., Beretta, G.D.

“…The term liquid biopsy (LB) refers to the use of various biological fluids as a surrogate for neoplastic tissue to achieve information for diagnostic,…”
Get full text

Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer by BERETTA, G. D, MICHETTI, G, BELOMETTI, M. O, GRITTI, G, QUADRI, A, POLETTI, P, LABIANCA, R

“…Cisplatin-based combinations are efficacious in increasing the overall survival of patients with non-small cell lung cancer (NSCLC), but their toxicity makes…”
Get full text

A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer by GRAZIANO, F, SANTINI, D, TESTA, E, CATALANO, V, BERETTA, G. D, MOSCONI, S, TONINI, G, LAI, V, LABIANCA, R, CASCINU, S

“…The incidence of gastric cancer (GC) increases significantly after the fifth decade and palliative chemotherapy is the ultimate treatment in the majority of…”
Get full text

Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) by Pedrazzoli, P., Lasagna, A., Cassaniti, I., Piralla, A., Squeri, A., Bruno, R., Sacchi, P., Baldanti, F., Di Maio, M., Beretta, G.D., Cinieri, S., Silvestris, N.

“…Patients with cancer have a well-known and higher risk of vaccine-preventable diseases (VPDs). VPDs may cause severe complications in this setting due to…”
Get full text

Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper by Gallo, M., Adinolfi, V., Morviducci, L., Acquati, S., Tuveri, E., Ferrari, P., Zatelli, M.C., Faggiano, A., Argentiero, A., Natalicchio, A., D'Oronzo, S., Danesi, R., Gori, S., Russo, A., Montagnani, M., Beretta, G.D., Di Bartolo, P., Silvestris, N., Giorgino, F.

“…Pancreatic cancer (PC) is a common cause of cancer-related death, due to difficulties in detecting early-stage disease, to its aggressive behaviour, and to…”
Get full text

Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology by Leone, A.G., Miceli, R., Trapani, D., Massagrande, M., Morano, F., Marsoni, S., La Verde, N., Berardi, R., Casolino, R., Lambertini, M., Dalu, D., Di Maio, M., Beretta, G.D., Perrone, F., Cinieri, S., Pietrantonio, F.

“…Transgender and gender-diverse (TGD) population represents an underserved group across the cancer care continuum. To assess the perspective of both oncology…”
Get full text

TAGS: A phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer by Arkenau, H.-T., Tabernero, J., Shitara, K., Dvorkin, M., Mansoor, W., Prokharau, A., Alsina, M., Ghidini, M., Faustino, C., Gorbunova, V., Zhavrid, E.A., Nishikawa, K., Hosokawa, A., Ganea, D., Yalçın, Ş, Beretta, G.D., Winkler, R.E., Makris, L., Doi, T., Ilson, D.H.

Get full text

Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper by Silvestris, N., Argentiero, A., Natalicchio, A., D'Oronzo, S., Beretta, G.D., Acquati, S., Adinolfi, V., Di Bartolo, P., Danesi, R., Faggiano, A., Ferrari, P., Gallo, M., Gori, S., Morviducci, L., Russo, A., Tuveri, E., Zatelli, M.C., Montagnani, M., Giorgino, F.

“…Most anticancer molecules are administered in body-size-based dosing schedules, bringing up unsolved issues regarding pharmacokinetic data in heavy patients…”
Get full text

Position paper of the Italian Association of Medical Oncology on the impact of COVID-19 on Italian oncology and the path forward: the 2021 Matera statement by Beretta, G.D., Casolino, R., Corsi, D.C., Perrone, F., Di Maio, M., Cinieri, S., Gobber, G., Bellani, M., Petrini, F., Zocchi, M.T., Traclò, F., Zagonel, V.

“…The coronavirus disease 2019 (COVID-19) pandemic has severely affected cancer care and research by disrupting the prevention and treatment paths as well as the…”
Get full text

Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: A low cost effective regimen by CASCINU, S, BALDELLI, A. M, BARNI, S, LABIANCA, R, FRONTINI, L, CURTI, C, CATALANO, G, CATALANO, V, GIORDANI, P, BERETTA, G. D, SILVA, R. R, GASPARINI, G, MARI, D, MAISANO, R, SALVAGNI, S

“…Recently, we reported a highly active regimen in advanced gastric cancer including a weekly administration of cisplatin, epidoxorubicin, leucovorin,…”
Get full text